In silico Safety Pharmacology
In silico Safety Pharmacology
批准号:
9288209
负责人:
COLLEEN E CLANCY
金额:
$68.87万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-07-05 至 2020-06-30
关键词:
AcademiaAction PotentialsAcuteAdverse effectsAffinityAmiodaroneAnti-Arrhythmia AgentsArrhythmiaBehaviorBiologicalCardiacCardiotoxicityCategoriesCellsClinical ResearchComplexComputer SimulationDangerousnessDataDependenceDevelopmentDrug IndustryDrug InteractionsDrug TargetingDrug toxicityElectrocardiogramEstrogensExhibitsExperimental ModelsFemaleGoalsGonadal Steroid HormonesGovernmentHeartHeart AbnormalitiesHumanIndustryIon ChannelKineticsLeadLettersLinkLong QT SyndromeMammalian CellMethodologyModelingMolecular ConformationMoxifloxacinNamesPharmaceutical PreparationsPharmacologyPharmacotherapyPhasePhysiologicalPotassium ChannelPreclinical Drug EvaluationProcessPropertyPublishingRehabilitation therapyRiskRisk FactorsRisk stratificationRoleSafetySotalolSpecificityStructureStructure-Activity RelationshipSurrogate MarkersSystemTestingTissuesToxic effectTriad Acrylic ResinVerapamilWorkanalogbasedesigndofetilidedrug candidatedrug developmentdrug discoverydrug mechanismdrug rehabilitationdrug testingexperimental studyfallshealthy volunteerheart electrical activityheart pharmacologyheart rhythmibutilideimprovedinterdisciplinary approachmathematical modelmulti-scale modelingnovelnovel strategiespre-clinicalpredictive modelingprototyperanolazinereceptorscreeningsexsimulationsubcellular targetingvirtual
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY: A major factor plaguing drug development is that there is no preclinical drug screen
that can accurately predict unintended drug induced cardiac arrhythmias. The current approaches rely on
substitute markers such as QT interval prolongation on the ECG. Unfortunately, QT prolongation is neither
specific nor sensitive to indicate likelihood of arrhythmias. There is an urgent need to identify a new approach
that can predict actual proarrhythmia rather than surrogate indicators. Mathematical modeling and simulation
constitutes one of the most promising methodologies to reveal fundamental biological principles and
mechanisms, model effects of interactions between system components and predict emergent drug effects.
Thus, we propose the development of a novel multiscale approach based on drug-channel structural
interactions and kinetics intended to predict drug induced cardiotoxicity in the context of: 1) preclinical drug
screening, 2) drug rehabilitation, and 3) prediction of the intersection of drug effects and coexistent risk factors.
Our underlying hypothesis is that the fundamental mode of drug interaction derived from each drug’s unique
structure activity relationship determines the resultant effects on cardiac electrical activity in cells and tissue.
By capturing these complex drug channel interactions in a model, we expect to be able to predict drug safety
or electro-toxicity in the heart. We have brought together an expert team to assemble and test a new multiscale
model framework that connects detailed mathematical models to predict atomic scale interactions of drugs on
the promiscuous hERG potassium channel to functional scale predictions at the level of the channel, cell and
tissue. Predictions from the atomic structure simulations will be used to inform the kinetic parameters of
models that capture the complex dynamical interactions of drugs and ion channels. The computational
components will then be studied in predictive models at the channel, cell and tissue scales to expose
fundamental mechanisms and complex interactions underlying emergent behaviors. Experiments in
mammalian cells and tissues will be undertaken to validate model predictions. Drug properties will be
perturbed in models to rehabilitate dangerous drugs and reduce their potential toxicity. The multiscale model
for prediction of cardiopharmacology that we will develop in this application will be applied to projects
demonstrating its usefulness for efficacy or toxicity of drug treatments in the complex physiological system of
the heart.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Multi-Scale Modeling of Vascular Signaling Units
-
批准号:10406687
-
项目类别:
-
资助金额:$22.73万
-
财政年份:2021
-
负责人:COLLEEN E CLANCY
-
依托单位:
Multi-Scale Modeling of Vascular Signaling Units
-
批准号:10394236
-
项目类别:
-
资助金额:$54.53万
-
财政年份:2020
-
负责人:COLLEEN E CLANCY
-
依托单位:
Multi-Scale Modeling of Vascular Signaling Units
-
批准号:10614418
-
项目类别:
-
资助金额:$54.53万
-
财政年份:2020
-
负责人:COLLEEN E CLANCY
-
依托单位:
Development of the Predictive NeuroCardiovascular Simulator
-
批准号:10397892
-
项目类别:
-
资助金额:$149.85万
-
财政年份:2018
-
负责人:COLLEEN E CLANCY
-
依托单位:
Development of the Predictive NeuroCardiovascular Simulator
-
批准号:10001997
-
项目类别:
-
资助金额:$69.19万
-
财政年份:2018
-
负责人:COLLEEN E CLANCY
-
依托单位:
Development of the Predictive NeuroCardiovascular Simulator
-
批准号:10092300
-
项目类别:
-
资助金额:$69.19万
-
财政年份:2018
-
负责人:COLLEEN E CLANCY
-
依托单位:
Development of the Predictive NeuroCardiovascular Simulator
-
批准号:10215080
-
项目类别:
-
资助金额:$145.07万
-
财政年份:2018
-
负责人:COLLEEN E CLANCY
-
依托单位:
In silico safety pharmacology
-
批准号:10480737
-
项目类别:
-
资助金额:$72.09万
-
财政年份:2016
-
负责人:COLLEEN E CLANCY
-
依托单位:
In silico safety pharmacology
-
批准号:10576790
-
项目类别:
-
资助金额:$72.64万
-
财政年份:2016
-
负责人:COLLEEN E CLANCY
-
依托单位:
In silico Safety Pharmacology
-
批准号:9176961
-
项目类别:
-
资助金额:$73.97万
-
财政年份:2016
-
负责人:COLLEEN E CLANCY
-
依托单位:
Predictive multiscale in silico cardio-pharmacology
-
批准号:9769117
-
项目类别:
-
资助金额:$77.18万
-
财政年份:2015
-
负责人:COLLEEN E CLANCY
-
依托单位:
Predictive multiscale in silico cardio-pharmacology
-
批准号:9332437
-
项目类别:
-
资助金额:$74.98万
-
财政年份:2015
-
负责人:COLLEEN E CLANCY
-
依托单位:
Pharmacogenomics and antiarrhythmic therapy: An in silico investigation
-
批准号:7788189
-
项目类别:
-
资助金额:$30.6万
-
财政年份:2007
-
负责人:COLLEEN E CLANCY
-
依托单位:
Pharmacogenomics and antiarrhythmic therapy: An in silico investigation
-
批准号:7261505
-
项目类别:
-
资助金额:$33.6万
-
财政年份:2007
-
负责人:COLLEEN E CLANCY
-
依托单位:
Pharmacogenomics and antiarrhythmic therapy: An in silico investigation
-
批准号:7407568
-
项目类别:
-
资助金额:$33.6万
-
财政年份:2007
-
负责人:COLLEEN E CLANCY
-
依托单位:
Pharmacogenomics and antiarrhythmic therapy: An in silico investigation
-
批准号:8048305
-
项目类别:
-
资助金额:$18.11万
-
财政年份:2007
-
负责人:COLLEEN E CLANCY
-
依托单位:
Pharmacogenomics and antiarrhythmic therapy: An in silico investigation
-
批准号:7586689
-
项目类别:
-
资助金额:$33.6万
-
财政年份:2007
-
负责人:COLLEEN E CLANCY
-
依托单位:
海外基金